Digestive Health

Amisulpride is a selective dopamine-2 and -3 receptor antagonist that inhibits postoperative nausea and vomiting.

Ulcerative colitis and Crohn disease are the two main forms of inflammatory bowel disease.

This month's featured products include empagliflozin, finerenone, and more.

The results of 3 phase 3 trials showed that the drug offered greater proportions of individuals with the condition who met the endpoints of clinical remission and endoscopic response.

For patients with celiac disease, eating gluten triggers an immune response in the small intestine.

Individuals in a study who received the food with BB-12 probiotic retained beneficial metabolites produced by the microbiota.

Crohn disease causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.

Ulcerative colitis affects the innermost lining of your large intestine and rectum.

Irritable bowel syndrome is the term for symptoms that occur when the contents of the large intestine move too quickly or too slowly.

Symptoms of IBD include diarrhea, fatigue, abdominal pain, cramping, blood in stool, reduced appetite, and weight loss.

Recent research has linked gut microbiota and cardiovascular disease with reported differences in gut microbial compositions among individuals with and without cardiovascular disease.

IBS can be caused by muscle contractions in the intestines, nervous system, severe infections, early life stress, and changes in the gut microbes.

NAFLD is a common comorbidity for patients with IBD.

The Crohn’s disease Exclusion Diet may help to increase the food options available for many children with the condition.

The gluten-like proteins found in ryegrass could be interacting with crops commonly used as wheat replacements, which may cause a reaction among people with celiac or gluten intolerance.

Because white meat, unprocessed red meat, dairy, starch, fruit, vegetables, and legumes were not associated with the development of IBD, the way that the food is processed may confer this risk of IBD, rather than the food itself.

According to the investigators, gene changes unique among individuals who responded to mirikizumab indicate that mirikizumab affects a distinct molecular healing pathway when compared to the spontaneous healing that occurred among the cohort administered the placebo.

Study’s secondary endpoints were also met, including the achievement of endoscopic improvement, histologic-endoscopic mucosal improvement, and corticosteroid-free clinical remission at week 52.

Other options for Crohn disease and ulcerative colitis include biologics, corticosteroids, immunosuppressants, and vedolizumab.

Investigators identified 2 subgroups at risk of developing bacterial biofilms: those who have taken a significant amount of medications over their lifetimes and those who have undergone organ transplants.

Clinicians can play an important role in counseling patients about the 5 main OTC categories of laxatives to treat this gastrointestinal condition.

A combination of 2 bacteria were able to stay in the colon for an extended amount of time, rather than passing through the system quickly like other probiotics.

The approval represents the first and only oral sphingosine 1-phosphate receptor modulator indicated for adults with moderately to severely active ulcerative colitis.

The body’s relationship with gut bacteria emerges after birth and in early infancy, during important immunological and physiological development.

Eating a lot of fat and sugar damage Paneth immune cells in the small intestine, which help regulate flora.

A study published in Nature may document a previously unknown interaction between gut microbes and the thymus, an immune system organ.

When a patient recovering from gonorrhea was fed the powder of the kuchila molung plant, the patient quickly suffered from much more than painful urination.

Models without the Gastrokine-1 protein weigh less and had lower levels of total body fat, despite consuming the same amount of food.

One of the first anti-obesity therapies to be introduced and marketed as a pharmaceutical was 2-4-Dinitrophenol, which entered the market around 1934.

The study investigated whether people who regularly ate higher quantities of nitrate-rich vegetables, such as leafy greens and beetroot, had lower blood pressure.